Pacific Biosciences
PACB
259 hedge funds and large institutions have $2.93B invested in Pacific Biosciences in 2023 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 86 increasing their positions, 60 reducing their positions, and 29 closing their positions.
220% more call options, than puts
Call options by funds: $59.3M | Put options by funds: $18.5M
86% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 29
60% more capital invested
Capital invested by funds: $1.83B → $2.93B (+$1.1B)
43% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 60
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more funds holding
Funds holding: 236 → 259 (+23)
3.1% more ownership
Funds ownership: 99.45% → 102.55% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$37.9M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$34.8M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$23.4M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$28.9M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$18.7M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$7.76M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$6.46M |
| 5 |
Millennium Management
New York
|
-$5.96M |
PACB Hedge Fund Activity: Q1 2023 in Review
259 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2023, worth a combined $2.93B — up 60% from $1.83B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new PACB positions and 29 closed out — a net gain of 25 holders — while 86 added to existing stakes and 60 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $41.9M. The largest seller was Jackson Square Partners, cutting an estimated $28.9M.
- 259 institutional investors held Pacific Biosciences (PACB) as of Q1 2023, up from 236 in Q4 2022.
- Funds reported $2.93B of Pacific Biosciences stock for Q1 2023, up 60% quarter-over-quarter.
- 54 funds opened new Pacific Biosciences positions in Q1 2023 and 29 closed out, a net change of +25 holders.
- The largest Pacific Biosciences buyer in Q1 2023 was Fidelity Investments, an estimated $41.9M added.
- The largest Pacific Biosciences seller in Q1 2023 was Jackson Square Partners, an estimated $28.9M sold.
Based on aggregated 13F filings for Q1 2023.